Loading…
Guangxi Yulin Pharmaceutical Group Co. Ltd. was cited for significant Current Good Manufacturing Practice (CGMP) violations in the manufacturing of finished pharmaceutical drugs following an FDA inspection in March 2025. The company failed to perform appropriate laboratory testing to determine identity and strength of active ingredients prior to drug product release and distribution, a repeat violation from a 2016 inspection, thereby producing adulterated drug products that did not conform to final specifications. The firm's response to FDA's initial inspection findings was deemed inadequate due to lack of supportive documentation and insufficient evidence of corrective actions taken to achieve compliance.